Reclast (zoledronic acid or zoledronate) is approved by the Food and Drug Administration (FDA) to treat and prevent osteoporosis in males, females after menopause, and people taking glucocorticoids.

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid Injection, USP in ...

Some say a new treatment for the bone-weakening disease is a breakthrough. May 2, 2007 — -- A new option in the treatment of osteoporosis could one day change the way many of the 10 million ...

Gland Pharma announced that it has received approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Zoledronic Acid Injection, 4 mg/100 ...

Reclast (zoledronic acid) is a medication that the Food and Drug Administration (FDA) has approved for preventing and treating osteoporosis in females after menopause, males, and individuals who take ...

Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.

Generic injectable and ophthalmic-focused Gland Pharma has received approval from the U.S. Food and Drug Administration for its abbreviated new drug application filed for Zoledronic Acid Injection, 4 ...

Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with osteoporosis. Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with ...

The U.S. Justice Department on Friday announced criminal charges against a State Department employee accused of sharing sensitive government information with people he met online, according to a ...

ZURICH, June 5 (Reuters) - U.S. regulators have broadened approval for use of Novartis AG's osteoporosis drug Reclast for prevention of new fractures in patients who have recently had a low-trauma ...